Hydantion Derivatives Synthesis and Activity Evaluation
Letters in Drug Design & Discovery, 2012, Vol. 9, No. 6 641
100 MHz) δ: 171.44, 156.96, 136.52, 128.53, 127.42,
127.42, 127.33, 127.33, 50.38, 45.26.
379.4; Anal. Calcd. for C23H26N2O3: C 72.99, H 6.92, N
7.40; Found C 72.96, H 6.91, N 7.41.
3-(2-(4-Isobutylphenyl)propanoyl)Imidazolidine-2,4-Dione
(7c)
General Procedure for the Compounds 3c-d
White solid, yield 75%; 1H-NMR(CDCl3, 400 MHz)δ:
0.87 (d, J = 6.64 Hz, 6H, 2×CH3), 1.49 (d, J = 6.96 Hz, 3H,
CH3), 1.83-1.85 (m, 1H, CH), 2.42 (d, J = 7.16 Hz, 2H,
CH2), 3.86 (d, J = 4.76 Hz, 2H, CH2), 4.81 (q, J = 6.96 Hz,
1H, CH), 5.94 (s, 1H, NH), 7.07 (d, J = 8.12 Hz, 2H,
2×ArH), 7.15 (d, J = 8.12 Hz, 2H, 2×ArH); 13C-
NMR(CDCl3, 100 MHz)δ:172.72, 168.52, 154.86,
141.07, 136.43, 129.66, 129.66, 127.61, 127.61, 46.96,
45.71, 44.99, 30.08, 22.35, 22.35, 18.44; ESI-MS (M++H),
m/z: 289.3; Anal. Calcd. for C16H20N2O3 : C 66.65, H 6.99, N
9.72; Found C 66.66, H 6.99, N 9.74.
Sodium metabisulphite (14.6 g, 0.077 mol), compound 4
(0.077 mol) and potassium cyanide (5.0 g, 0.077 mol) was
dissolved in 20 mL water, stirred at room temperature for 0.5
h to get cyanohydrin derivatives 5. Ammonium carbonate
(14.8 g, 0.154 mol) was then added. The mixture was heated
to 50℃ for half an hour, and the temperature was raised to
90℃ and heated for another 3 h. The solvent was evaporated
under reduced pressure. The crude product was recrystallized
with hot water to get pure product 3c-d as white solid.
Imidazolidine-2, 4-Dione (3c)
Yield 42%; 1H-NMR(DMSO-d6, 400 MHz) δ: 3.84 (s,
2H, CH2), 7.67 (s, 1H, NH), 10.59 (s, 1H, NH); 13C-
NMR(DMSO-d6, 100 MHz) δ: 174.26, 158.74, 47.56.
3-(2-(4-Isobutylphenyl)propanoyl)-5,5-
Dimethylimidazolidine-2,4-Dione (7d)
White solid, yield 85%; 1H-NMR (CDCl3, 400
MHz)δ:0.85 (d, J = 6.6 Hz, 6H, 2×CH3), 1.23 (d, J = 11.2
Hz, 6H, 2×CH3), 1.48 (d, J = 6.96 Hz, 3H, CH3), 1.80-1.82
(m, 1H, CH), 2.42 (d, J = 7.16 Hz, 2H, CH2), 4.75 (q, J =
6.96 Hz, 1H, CH), 6.08 (s, 1H, NH), 7.06 (d, J = 8.0 Hz, 2H,
5, 5-Dimethylimidazolidine-2, 4-Dione (3d)
Yield 48%; 1H-NMR(DMSO-d6, 400 MHz) δ: 1.44 (s,
6H, 2×CH3), 7.82 (s, 1H, NH), 10.68 (s, 1H, NH); 13C-
NMR(DMSO-d6, 100 MHz) δ: 181.78, 158.49, 61.35,
24.26.
2×ArH), 7.11 (d,
J =
8.0 Hz, 2H, 2×ArH); 13C-
NMR(CDCl3, 100 MHz)δ:174.39, 172.89, 152.60,
141.01, 136.75, 129.58, 129.58, 127.62, 127.62, 58.02,
47.17, 44.93, 30.1, 24.92, 24.92, 22.24, 22.24, 17.93; ESI-
MS (M++H), m/z: 317.4, Anal. Calcd. for C18H24N2O3 : C
68.33, H 7.65, N 8.85; Found C 68.34, H 7.64, N 8.86.
General Procedure for the Compounds 7a-d
Ibuprofen (0.5 g, 0.002 mol), SOCl2(0.48 g, 0.004 mol)
added into CH2Cl2 10 ml, stirred at reflux for 2 h, then added
into compound 3 (0.002 mol) were dissolved in pyridine 10
mL, reacted at room temperature overnight. By evaporating
the solvent, compound 7 was obtained through flash
chromatography (methanol / chloroform 1/20).
CONCLUSION
In summary, a series of novel hydantion derivatives were
synthesized and evaluated for their anti-inflammatory and
antitussive activity. These SAR studies revealed that the
substitution of methyl and hydrogen at the N1 position of
hydantoin had pronounced influence on antitussive activity.
It's noteworthy to mention that compound 7a showed two-
fold stronger anti-inflammatory activity than Ibuprofen.
Further extensive studies are required to be carried out to
determine their mechanism of action.
3-(2-(4-Isobutylphenyl)Propanoyl)-1-Methylimidazolidine-
2,4-Dione (7a)
White solid, yield 82%; 1H-NMR(CDCl3, 400
MHz)δ:0.89 (d, J = 6.8 Hz, 6H, 2×CH3), 1.49 (d, J = 6.8
Hz, 3H, CH3), 1.83-1.85 (m, 1H, CH), 2.42 (d, J = 7.2 Hz,
2H, CH2), 2.93 (s, 3H, CH3), 3.77 (s, 2H, CH2), 4.85 (q, J =
6.8 Hz, 1H, CH), 7.07 (d, J = 8.0 Hz, 2H, 2×ArH), 7.16 (d, J
= 8.0 Hz, 2H, 2×ArH); 13C-NMR(CDCl3, 100 MHz)δ:
172.58, 166.93, 152.86, 140.88, 136.68, 129.57, 129.57,
127.64, 127.64, 50.85, 46.62, 44.97, 30.06, 29.52, 22.32,
22.32, 18.57; ESI-MS (M++H), m/z: 303.3; Anal. Calcd. for
C17H22N2O3: C 67.53, H 7.33, N 9.26; Found C 67.55, H
7.32, N 9.25.
CONFLICT OF INTEREST
Declared none.
ACKNOWLEDGEMENTS
1-Benzyl-3-(2-(4-isobutylphenyl)Propanoyl)Imidazolidine-
2,4-Dione (7b)
This work was supported by the Natural Medicinal
Chemistry Department of the College of Pharmacy Jilin
University.
Oil, yield 90%; 1H-NMR(CDCl3, 400 MHz)δ:0.89
(d, J = 6.56 Hz, 6H, 2×CH3), 1.50 (d, J = 6.92 Hz, 3H, CH3),
1.84-1.86 (m, 1H, CH), 2.44 (d, J = 7.16 Hz, 2H, CH2), 3.60
(dd, J1 = 17.72 Hz, J2 = 25.0 Hz, 2H, CH2), 4.46 (dd, J1 =
14.96 Hz, J2 = 6.4 Hz, 2H, CH2), 4.87 (q, J = 6.96 Hz, 1H,
CH), 7.11-7.18 (m, 6H, 6×ArH), 7.32 (m, 3H, 3×ArH); 13C-
NMR(CDCl3, 100 MHz)δ: 172.60, 166.88, 152.84,
140.93, 136.69, 134.42, 129.60, 129.60, 129.02, 129.02,
128.33, 128.00, 128.00, 127.68, 127.68, 48.24, 46.83, 46.44,
45.00, 30.10, 22.34, 22.34, 18.39; ESI-MS (M++H), m/z:
REFERENCES
[1]
[2]
[3]
Williams, D.A.; Lemke, T.L. Foye's Principles of Medicinal
Chemistry, 5th ed.; Lippincott Williams & Wilkins: Philadelphia,
2002.
Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D. Pharmaceutical
Substances, Synthesis,Patents, Applications, 4th ed.; Thieme:
Stuttgart, 2001.
Malawska, B. New anticonvulsant agents. Curr. Topics Med.
Chem., 2005, 5, 69-85.